Scarica l'app Stockscreener
6.50
1.14%
-0.075
Dopo l'orario di chiusura:
6.52
0.02
+0.31%
Precedente Chiudi:
$6.575
Aprire:
$6.53
Volume 24 ore:
173.97K
Relative Volume:
0.49
Capitalizzazione di mercato:
$252.33M
Reddito:
$5.74M
Utile/perdita netta:
$-166.12M
Rapporto P/E:
-1.6259
EPS:
-3.9978
Flusso di cassa netto:
$-131.64M
1 W Prestazione:
+2.04%
1M Prestazione:
+1.88%
6M Prestazione:
-42.83%
1 anno Prestazione:
-12.28%
Intervallo 1D:
$6.35
$6.62
Intervallo di 1 settimana:
$5.76
$6.72
Portata 52W:
$4.93
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Nome
Entrada Therapeutics Inc
Settore
Industria
Telefono
857-305-1825
Indirizzo
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.50 | 255.25M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-11 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Oppenheimer | Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-01-05 | Iniziato | Oppenheimer | Outperform |
| 2023-04-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97 - Stock Titan
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan
Entrada Therapeutics (TRDA) director receives 19,000-share stock option grant - Stock Titan
Entrada Therapeutics (TRDA) Gains Ground: Modest Rally Tests Key Resistance LevelsDay Trade Opportunities - newsline.com
Entrada Therapeutics Stockholders Approve Directors and Equity Plans - TipRanks
[8-K] Entrada Therapeutics, Inc. Reports Material Event - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) - The Globe and Mail
Entrada Therapeutics Inc. (TRDA) Q1 2026 Earnings: Narrower Loss Surprises, but No Revenue Weighs on SharesROIC Trend Report - newsline.com
Discipline and Rules-Based Execution in TRDA Response - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
TRDA: Strong safety and early efficacy in DMD trials drive confidence in a growing clinical pipeline - TradingView
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial - Pluang
Entrada gets clearance to escalate dose in DMD trial By Investing.com - Investing.com South Africa
Entrada gets clearance to escalate dose in DMD trial - Investing.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study - The Manila Times
Rare disease trial tests DMD treatment with once-every-six-week dosing - Stock Titan
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-27 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out | NDAQ:TRDA | Press Release - Stockhouse
Behavioral Patterns of TRDA and Institutional Flows - Stock Traders Daily
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TRDA - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Entrada Therapeutics clinical trial data sparks brutal stock selloffhere's why - MSN
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock By Investing.com - Investing.com India
Insider Move at Entrada Therapeutics Sparks Fresh Investor Interest - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Entrada Thera - The National Law Review
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock - Investing.com
Entrada Therapeutics (TRDA) director’s trust buys 5,000 common shares - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutic - The National Law Review
Entrada Therapeutics Reports Positive Phase 1/2 Results for ENTR-601-44 in Duchenne Muscular Dystrophy, Highlighting Best-in-Class Potential and $5B U.S. Market Opportunity 679 - Minichart
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
User - The Chronicle-Journal
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress - TipRanks
Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026 - TradingView
Entrada Therapeutics (TRDA) furnishes updated corporate presentation to investors - Stock Titan
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC - GlobeNewswire
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Scott Coop
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
(TRDA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Entrada Therapeutics faces investigation after drug trial results disappoint, stock plunges 57%. - Pluang
Entrada Therapeutics, Inc. Common Stock (TRDA) Stock Price Today & Analysis - Gotrade
Entrada Therapeutics Inc Azioni (TRDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Entrada Therapeutics Inc Azioni (TRDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sethuraman Natarajan | President, Research & Develop. |
May 04 '26 |
Sale |
15.39 |
25,907 |
398,810 |
216,317 |
| Dowden Nathan J | President & COO |
May 04 '26 |
Option Exercise |
1.74 |
15,000 |
26,100 |
213,588 |
| Dowden Nathan J | President & COO |
May 04 '26 |
Sale |
15.33 |
15,000 |
229,953 |
198,588 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):